Literature DB >> 17702089

Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.

A C J van Akkooi1, M G Bouwhuis, J H W de Wilt, M Kliffen, P I M Schmitz, A M M Eggermont.   

Abstract

BACKGROUND: Sentinel node (SN) status is the most important prognostic factor for overall survival in stage I or II melanoma. Yet SN-positive tumours with submicroscopic involvement of the SN (clusters of cells smaller than 0.1 mm) have shown a distant recurrence rate of only 9 per cent at 5 years, as good as that in SN-negative patients. This study compared the outcome after completion lymph node dissection (CLND) in SN-positive tumours with elective total lymph node dissection (TLND) in patients with palpable nodes.
METHODS: A total of 188 patients were identified; 124 had TLND and 64 had CLND. Median follow-up was 56 and 37 months respectively. There were no significant differences between the groups regarding tumour Breslow thickness, ulceration and site of the primary tumour. Survival rates were calculated from date of primary excision. All patients with primary melanomas on extremities or trunk were included.
RESULTS: On univariable analysis, the site of the primary tumour (extremity versus trunk) (P < 0.001), Breslow thickness (P = 0.005) and ulceration (P < 0.001) were prognostic for overall survival. There was a non-significant 13 per cent difference in overall survival at 5 years between CLND and TLND (P = 0.115). Excluding 15 patients who had SN disease with submicrometastases reduced the difference to 6 per cent (P = 0.415).
CONCLUSION: This study showed no significant survival benefit for SN-positive CLND compared with TLND, especially when patients with nodes containing submicrometastases were excluded. Copyright (c) 2007 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17702089     DOI: 10.1002/bjs.5814

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma.

Authors:  Ingo Stoffels; Markus Müller; Marie Henrike Geisel; Julia Leyh; Thorsten Pöppel; Dirk Schadendorf; Joachim Klode
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-25       Impact factor: 9.236

2.  Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial.

Authors:  Ingo Stoffels; Ken Herrmann; Jan Rekowski; Philipp Jansen; Dirk Schadendorf; Andreas Stang; Joachim Klode
Journal:  Trials       Date:  2019-02-04       Impact factor: 2.279

Review 3.  Melanoma and nuclear medicine.

Authors:  Andrés Perissinotti; Sergi Vidal-Sicart; Omgo Nieweg; Renato Valdés Olmos
Journal:  Melanoma Manag       Date:  2014-09-05

4.  Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma.

Authors:  David Y Lee; Briana J Lau; Kelly T Huynh; Devin C Flaherty; Ji-Hey Lee; Stacey L Stern; Steve J O'Day; Leland J Foshag; Mark B Faries
Journal:  J Am Coll Surg       Date:  2016-01-29       Impact factor: 6.113

Review 5.  Importance of tumor load in the sentinel node in melanoma: clinical dilemmas.

Authors:  Alexander C J van Akkooi; Cornelis Verhoef; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2010-06-22       Impact factor: 66.675

Review 6.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

7.  Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Authors:  Kalijn F Bol; Erik H J G Aarntzen; Florentien E M In 't Hout; Gerty Schreibelt; Jeroen H A Creemers; W Joost Lesterhuis; Winald R Gerritsen; Dirk J Grunhagen; Cornelis Verhoef; Cornelis J A Punt; Johannes J Bonenkamp; Johannes H W de Wilt; Carl G Figdor; I Jolanda M de Vries
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

Review 8.  Melanoma & nuclear medicine: new insights & advances.

Authors:  Andrés Perissinotti; Daphne Dd Rietbergen; Sergi Vidal-Sicart; Ana A Riera; Renato A Valdés Olmos
Journal:  Melanoma Manag       Date:  2018-06-28

9.  Cutaneous melanoma and sentinel lymph node biopsy.

Authors:  A C J van Akkooi; J H W de Wilt; C Verhoef; A M M Eggermont
Journal:  Ann Surg Oncol       Date:  2008-02-02       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.